Various HIF-1α indirect inhibitors have been developed, with Rapamycin, Cetuximab, Romidepsin, and Vorinostat receiving FDA approval for the treatment of a variety of cancer types; however, as previously mentioned, no direct HIF-1α inhibitors are currently on the market [239,240]. The gene discussed is HIF1A; the disease is cancer.